Literature DB >> 9761357

Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma.

P C Koch Nogueira1, A Hadj-Aïssa, M Schell, L Dubourg, M Brunat-Mentigny, P Cochat.   

Abstract

The acute renal effects of chemotherapy are known, but long-term nephrotoxicity has rarely been investigated. The aim of the present study was to assess long-term renal function in children and adolescents who received at-risk chemotherapy, including cisplatin, ifosfamide, and methotrexate, to treat an osteosarcoma. Renal function tests [creatinine clearance, microalbuminuria, and renal excretion of sodium, potassium, chloride, calcium, magnesium (Mg), phosphorus (P), and uric acid] were prospectively performed 5.4+/-2.2 (+/-SD) years after chemotherapy (total cumulative dose: methotrexate 41+/-31 g/m2, ifosfamide 39+/-14 g/m2, cisplatin 674+/-188 mg/m2) in 18 children and adolescents. The results were compared with 13 normal volunteers matched for age and sex. Creatinine clearance, which was greater than 80 ml/min per 1.73 m2 in all patients, correlated with the total dose of ifosfamide (r=0.55, P<0.05) and cisplatin (r=0.48, P<0.05). Microalbuminuria was noted in 4 patients. Hypomagnesemia was present in 4 and hypercalciuria in 3 patients; renal excretion of P, Mg, and uric acid was higher in patients than in controls. Glomerular function was not significantly altered and only mild tubular dysfunction was present. Since renal excretion of P and Mg were increased in patients compared with normal volunteers and hypercalciuria was occasionally seen, divalent ion disorders are the most-likely potential complications.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9761357     DOI: 10.1007/s004670050507

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  13 in total

1.  Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury.

Authors:  Yan Yu; Hong Jin; Daniel Holder; Josef S Ozer; Stephanie Villarreal; Paul Shughrue; Shu Shi; David J Figueroa; Holly Clouse; Ming Su; Nagaraja Muniappa; Sean P Troth; Wendy Bailey; John Seng; Amy G Aslamkhan; Douglas Thudium; Frank D Sistare; David L Gerhold
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908

Review 2.  Drug-induced hypomagnesaemia : scope and management.

Authors:  Jacob Atsmon; Eran Dolev
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  A basic science view of acute kidney injury biomarkers.

Authors:  Jennifer R Charlton; Didier Portilla; Mark D Okusa
Journal:  Nephrol Dial Transplant       Date:  2014-01-02       Impact factor: 5.992

4.  Effect of silymarin in the prevention of Cisplatin nephrotoxicity, a clinical trial study.

Authors:  Ali Momeni; Ali Hajigholami; Shohreh Geshnizjani; Soleiman Kheiri
Journal:  J Clin Diagn Res       Date:  2015-04-01

5.  Renal function during and after treatment for acute lymphoblastic leukemia in children.

Authors:  Maryna Krawczuk-Rybak; Marta Kuźmicz; Jolanta Wysocka
Journal:  Pediatr Nephrol       Date:  2005-03-22       Impact factor: 3.714

6.  Magnesium metabolism and its disorders.

Authors:  R Swaminathan
Journal:  Clin Biochem Rev       Date:  2003-05

Review 7.  Biomarkers of nephrotoxic acute kidney injury.

Authors:  Michael A Ferguson; Vishal S Vaidya; Joseph V Bonventre
Journal:  Toxicology       Date:  2008-01-04       Impact factor: 4.221

Review 8.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

Review 9.  Biomarkers of acute kidney injury.

Authors:  Vishal S Vaidya; Michael A Ferguson; Joseph V Bonventre
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

Review 10.  Anticancer drug-induced kidney disorders.

Authors:  P E Kintzel
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.